Clinical Trials Browser

Unknown × NETWORK × Carcinoma, Non-Small-Cell Lung × Clear all

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05254119 2024-04-04

REGISTURK-LUNG

Unknown

6,000 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT03827070 2023-04-25

DPTA

Phase 1 Unknown

12 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04530708 2020-08-28

MARS

Phase NA Unknown

162 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01795521 2020-01-31

LungTech

Phase 2 Unknown

39 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02273271 2015-10-30

EVIDENCE

Phase NA Unknown

31 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01920789 2014-12-09

SPACE

Phase NA Unknown

102 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01497041 2011-12-22

A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment

Phase 2 Unknown

35 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT00516100 2010-01-15

Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC

Phase 1/2 Unknown

62 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

POSTILV

REGISTURK-LUNG

DPTA

MARS

LungTech

EVIDENCE

SPACE

A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment

Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC